Financial Results for the Second Quarter of Fiscal Year Ending March 31, 2025 (FY2024)

from the beginning

Financial Results for the Second Quarter of Fiscal Year Ending March 31, 2025 (FY2024)

• Forward-Looking Statements and Use of Document

• Highlights

• P&L, FCF

• OP Variance Analysis (Q2): Continued demand and foreign exchange effects contributed

• OP Variance Analysis (Q2 YTD):Contribution from pricing measures and strong sales

• Revenue by Region:Steady progress in all regions, led by US and Europe

• C&V:Both sales and profits exceeded planned figures, driven by US and Europe

• TMCS:Revenues and profits increased due to strong sales including one-time factors and the effects of pricing measures

• TBCT:Revenues and profits increased due to strong performance by the blood center business

• Free Cash Flow:62.1 B JPY(YoY +44.6 B JPY)

• Upward revision of FY24 guidance due to strong performance and FX effects

• Key points of the upward revision of adjusted operating profit

Reference

• P&L (QoQ)

• SG&A (QoQ)

• SG&A (YoY)

• Adjusted Operating Profit: Adjustments

• CAPEX, Depreciation andAmortization,R&D Expenses

• Cash Flow (Q2 YTD)

• Cash Flow (Q2)

• Foreign Exchange Sensitivity

@

Beyond GS26: Innovation Strategy

• Forward-Looking Statements and Use of Document

• Commitment to Innovation

• Progress of GS26 Sales Growth Drivers

• Innovation at Terumo

• Further Pipeline Expansion Through Innovation

• Venous Thromboembolism (VTE) and Market Overview

• Venous Business Strategy

• Venous Product R&D

• Venous Pipeline and Estimated Sales

• Corporate Venture Capital (CVC)

• Venture Capital Market and Terumo's Portfolio

• Use of Digital Technology

• Taking Healthcare to New Heights

@